Brief: U.S. Court Of Appeals For The Federal Circuit Affirms Prior Delaware District Court Rulings In Favor Of Acadia In Nuplazid® (Pimavanserin) Composition Of Matter Patent
09/06/2025 21:03
ACADIA Pharmaceuticals Inc ACAD.O: U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT AFFIRMS PRIOR DELAWARE DISTRICT COURT RULINGS IN FAVOR OF ACADIA IN NUPLAZID® (PIMAVANSERIN) COMPOSITION OF MATTER PATENT ACADIA PHARMACEUTICALS INC - NUPLAZID PATENT PROTECTION EXTENDED TO 2030 Source text: ID:nBw1cL5Rza Further company coverage: ACAD.O
Recent news on Acadia Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study (updated)
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry